NuGenerex Therapeutics

NuGenerex Therapeutics, a subsidiary of Generex Biotechnology, is a biopharmaceutical company focused on developing immunotherapies and drug delivery systems. The company's core technology, the Ii-Key platform, is designed to modulate the immune system by enhancing the presentation of antigens to CD4+ T-helper cells, with applications in oncology and infectious disease vaccines. Additionally, the company utilizes its proprietary RapidMist buccal delivery system for the needle-free administration of biologics, most notably for its flagship product, Oral-lyn (buccal insulin). NuGenerex operates through several specialized subsidiaries to manage its diverse portfolio of metabolic, orthopedic, and immunotherapy assets.